Aldecoa KAT, Macaraeg CSL, Dadlani A, Yadlapalli S. Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.
Case Rep Hematol 2023;
2023:1691996. [PMID:
38130705 PMCID:
PMC10735723 DOI:
10.1155/2023/1691996]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 11/28/2023] [Accepted: 11/29/2023] [Indexed: 12/23/2023] Open
Abstract
Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.
Collapse